VEGFA and neoplasm: The underlying molecular mechanisms of action of the potent anti-cancer effects of ABL001 with chemotherapy might be due to the optimal combination effects of cytotoxic activity on tumor cells by paclitaxel or irinotecan together with more potent anti-angiogenic activity on tumor endothelial cells by ABL001, a VEGF, and DLL4 dual inhibitor.